PLA2R和THSD7A在原发性膜性肾病临床诊断中的研究进展

Research progress of PLA2R combined with THSD7A in the clinical diagnosis of primary membranous nephropathy

膜性肾病(MN)是肾病综合征病理类型之一,包含原发性和继发性两种类型。目前诊断主要依靠肾组织病理检测等有创检查,但对行肾穿刺活检有禁忌的患者受限,因此寻找特异性血清靶蛋白指标诊断原发性MN显得极为重要。磷脂酶A2受体(PLA2R)及1型血小板反应蛋白7A域(THSD7A)的检测在诊断MN、监测原发性MN患者临床病情活动中有重要意义,特别对存在肾脏穿刺禁忌证的病人尤为重要。该文就PLA2R、THSD7A在原发性MN的发病机制、疾病诊断、病情活动度、疾病治疗、预后监测相关性的研究进展进行综述。

Membranous nephropathy(MN)is one of the pathological types of nephrotic syndrome.It contains two types:primary MN and secondary MN.At present,the diagnosis mainly relies on invasive examination such as the pathological examination of renal tissue pathological examination,but it has a limited effect on patients who have contraindications for renal biopsy.Therefore,it is extremely important to find a specific serum target protein index for the diagnosis of primary MN.The detection of M-type phospholipase A2 receptor(PLA2R)and Thrombospondin type-1 domain-containing 7A(THSD7A)is of great significance in the diagnosis of MN and the monitoring of clinical activity in patients with primary MN,especially those who have contraindications for renal biopsy.This article reviews the research progress of PLA2R and THSD7A in the pathogenesis,the diagnosis,activity and treatment of the disease and prognosis monitoring of primary MN.